Press Releases

Press Releases

View all news
Voronoi's Non-Small Cell Lung Cancer Therapy Selected for Korea Drug Development Fund Project
2022.08.12
⚫ Non-clinical research funding for therapy targeting the Tagrisso-resistant C797S mutation in lung cancer
⚫ CEO Daekwon Kim: "Excellent selectivity and brain penetrance in preclinical studies; Phase 1 clinical trial next year"

Voronoi (CEOs Daekwon Kim and Hyuntae Kim), a global drug design company, announced on the 12th that 'VRN11,' which it is developing as a next-generation precision targeted therapy for non-small cell lung cancer, has been selected as a new non-clinical support project by the Korea Drug Development Fund (KDDF, Director Hyunsang Mook).

With this selection for the Korea Drug Development Fund project, Voronoi will receive approximately KRW 1.2 billion in preclinical R&D funding for VRN11 over two years.

VRN11 is a kinase inhibitor that precisely targets the epidermal growth factor receptor (EGFR) C797S mutation, which emerges through drug resistance after non-small cell lung cancer patients are treated with third-generation targeted therapies such as Tagrisso (osimertinib), as well as other rare EGFR mutations. Voronoi stated that in earlier preclinical studies it confirmed selectivity and brain penetrance surpassing those of the EGFR non-small cell lung cancer targeted therapies launched or under development by global competitors. Voronoi plans to present VRN11's preclinical research data for the first time at the American Association for Cancer Research (AACR) meeting this October.
In last year's inaugural Korea Drug Development Fund program, Voronoi and its wholly owned subsidiary B2S Bio (CEO Hwankeun Choi) had their MPS1-inhibiting targeted therapy and HER2-positive breast cancer therapeutic compound selected as non-clinical research and drug candidate discovery projects, respectively.
CEO Daekwon Kim of Voronoi said, "Being selected for the Korea Drug Development Fund project again this year, following last year, has once again confirmed Voronoi's technological strength. We plan to accelerate R&D on VRN11 and enter a Phase 1 clinical trial next year."
Based on its unrivaled drug design technology, Voronoi has developed numerous compounds with exceptionally high selectivity and blood-brain-barrier penetration, completing a total of four license-out deals in 2020 and last year, including three license-out deals to the U.S. Its track record amounts to KRW 2.1 trillion.